SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SRGN ( Seragen, Inc.)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dwight martin who wrote (32)4/1/1998 3:44:00 PM
From: Henry Niman  Read Replies (1) of 52
 
I believe that SRGN just gets reimbursement for manufacturing costs for DAB389IL-2 applications for CTCL (SRGN still has rights for psoriasis). Although the SEC documents filed by LGND mention SRGN, they don't indicate that LGND has accepted the compound from LLY. LGND may still elect to take the cash and a higher royalty on their rexinoid.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News